hotspot -WSS

hotspot

author：knowledge 2025-09-27 23:33:45 - browse：779

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： STAT Madness 2024: Meet the contenders

WSS

World's first CRISPR

Doctor of U.S. President Joe Biden says he is fit for duty

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Using force crossed my mind when examining a defiant young patient

PBM reforms clear House panel

Congress must reauthorize a committee to support older Americans

explore

hotspot

entertainment

In Memoriam: Notable people who died in 2023

Are embryos people? Reproductive medicine's future depends on the answer

Medical records are filled with copy

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

State Dept. review finds Biden bears some blame for Afghanistan failures

Ransomware attacks on hospitals: Study outlines patient impact

Peter Hotez and the public health issue of online harassment

Cholera vaccine supplies dangerously low, outbreaks surging

Affirmative action in medical school literally saved lives

Congress must reauthorize a committee to support older Americans

leisure time

CRISPR pioneers react to Casgevy, first gene

David Sabatini, ex

Hospitals look to new technology to keep health care workers safe

Are embryos people? Reproductive medicine's future depends on the answer

Cholera vaccine supplies dangerously low, outbreaks surging

STAT Madness 2024: Meet the contenders

hotspot

focus

hotspot

focus